American scientists have developed an innovative, non-surgical nanotherapy that eliminates aggressive brain tumor cells, glioblastoma, in mouse models. This achievement provides a new, highly promising mechanism in the field of immunotherapeutic treatment for brain cancer.
Glioblastoma (GBM) represents one of the most malignant and resistant neoplasms of the central nervous system. The scientists created a nano-delivery system that is applied via intranasal application (nasal droplets) and successfully crosses the Blood-Brain Barrier (BBB) to reach the brain parenchyma without surgical invasion.
The mechanism of the therapy is based on activating the local immune system of the brain. The treatment utilizes gold core-based Spherical Nucleic Acids (SNAs) that directly activate the STING (STimulator of INterferon Genes) signaling pathway.
STING activation triggers the release of interferon and other pro-inflammatory cytokines, which transforms “silent” (immunosuppressive) tumors into targets visible and open to the immune system (Immunogenic). As a result, the body’s cytotoxic T-lymphocytes (protective cells) begin destroying the tumor cells.
In experimental studies, the researchers paired the nanotherapy with Immune Checkpoint Inhibitors, drugs that enhance the anti-tumor activity of T-cells.
This combined approach led to the complete elimination (liquidation) of the tumor mass in mice. Notably, the treatment provided long-lasting immunological memory (adaptive immunity), which prevented tumor growth even upon re-injection of the tumor.
These results point to a promising new strategy for treating glioblastoma, which bypasses invasive methods and uses the body’s own immune mechanisms to fight the tumor. The researchers are hopeful that this therapeutic platform will undergo clinical testing in the future.
